Service des Maladies de L'appareil Digestif et Unité INSERM 995, Hôpital Huriez, Rue Polonovski, 59037 Lille Cedex, France.
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):231-42. doi: 10.1038/nrgastro.2015.35. Epub 2015 Mar 17.
Alcoholic liver disease (ALD) is a complex process that includes a wide spectrum of hepatic lesions, from steatosis to cirrhosis. Cell injury, inflammation, oxidative stress, regeneration and bacterial translocation are key drivers of alcohol-induced liver injury. Alcoholic hepatitis is the most severe form of all the alcohol-induced liver lesions. Animal models of ALD mainly involve mild liver damage (that is, steatosis and moderate inflammation), whereas severe alcoholic hepatitis in humans occurs in the setting of cirrhosis and is associated with severe liver failure. For this reason, translational studies using humans and human samples are crucial for the development of new therapeutic strategies. Although multiple attempts have been made to improve patient outcome, the treatment of alcoholic hepatitis is still based on abstinence from alcohol and brief exposure to corticosteroids. However, nearly 40% of patients with the most severe forms of alcoholic hepatitis will not benefit from treatment. We suggest that future clinical trials need to focus on end points other than mortality. This Review discusses the main pathways associated with the progression of liver disease, as well as potential therapeutic strategies targeting these pathways.
酒精性肝病(ALD)是一个复杂的过程,包括从脂肪变性到肝硬化的广泛的肝损伤。细胞损伤、炎症、氧化应激、再生和细菌易位是酒精引起肝损伤的关键驱动因素。酒精性肝炎是所有酒精性肝损伤中最严重的形式。ALD 的动物模型主要涉及轻度肝损伤(即脂肪变性和中度炎症),而人类的严重酒精性肝炎发生在肝硬化的背景下,并与严重肝衰竭相关。出于这个原因,使用人和人类样本的转化研究对于开发新的治疗策略至关重要。尽管已经多次尝试改善患者的预后,但酒精性肝炎的治疗仍然基于戒酒和短暂使用皮质类固醇。然而,近 40%的最严重形式的酒精性肝炎患者不会从治疗中受益。我们建议未来的临床试验需要关注除死亡率以外的终点。本综述讨论了与肝病进展相关的主要途径,以及针对这些途径的潜在治疗策略。